Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) EBITDA (2016 - 2025)

Historic EBITDA for Lemaitre Vascular (LMAT) over the last 16 years, with Q3 2025 value amounting to $20.3 million.

  • Lemaitre Vascular's EBITDA rose 5448.74% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.9 million, marking a year-over-year increase of 2484.68%. This contributed to the annual value of $52.3 million for FY2024, which is 4234.04% up from last year.
  • Per Lemaitre Vascular's latest filing, its EBITDA stood at $20.3 million for Q3 2025, which was up 5448.74% from $16.1 million recorded in Q2 2025.
  • Over the past 5 years, Lemaitre Vascular's EBITDA peaked at $20.3 million during Q3 2025, and registered a low of $5.8 million during Q2 2022.
  • Moreover, its 5-year median value for EBITDA was $9.5 million (2023), whereas its average is $10.6 million.
  • In the last 5 years, Lemaitre Vascular's EBITDA surged by 12795.57% in 2021 and then tumbled by 4792.0% in 2022.
  • Over the past 5 years, Lemaitre Vascular's EBITDA (Quarter) stood at $8.3 million in 2021, then dropped by 16.07% to $7.0 million in 2022, then soared by 46.49% to $10.2 million in 2023, then increased by 25.95% to $12.9 million in 2024, then soared by 58.02% to $20.3 million in 2025.
  • Its EBITDA stands at $20.3 million for Q3 2025, versus $16.1 million for Q2 2025 and $12.6 million for Q1 2025.